論文・技術情報追加のお知らせ

1. Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases.

酢酸グラチラマー関連アナフィラキシーのFAERS等による特徴解析。

対象DB：FAERS

2. Signal detection and analysis of adverse events associated with sevelamer post-marketing based on the FAERS database.

セベラマーの市販後有害事象におけるFAERSシグナル解析。

対象DB：FAERS

3. A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database.

血液がん治療用新世代ADCにおける心臓有害事象の不均衡分析。

対象DB：FAERS

4. Sepsis reporting signals associated with endothelin receptor antagonists and IFITM3-Centered interferon-responsive monocyte features: a pharmacovigilance and transcriptomic study.

エンドセリン受容体拮抗薬関連敗血症シグナルと転写産物解析。

対象DB：FAERS

5. Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database.

FAERSにおける適応外ガラス体注射ベバシズマブの不均衡分析。

対象DB：FAERS

6. The real-world safety of ruxolitinib in graft-versus-host disease treatment: a pharmacovigilance study based on the FDA adverse event reporting system.

FAERSを用いたGVHD治療におけるルキソリチニブの安全性評価。

対象DB：FAERS

7. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitors in NSCLC: Insights From Pharmacovigilance Data, a Retrospective Case-control Study, and Single-cell RNA Sequencing Dataset.

非小細胞肺がんにおけるICI関連甲状腺有害事象の不均衡分析。

対象DB：FAERS

8. Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis.

FAERSにおけるCDK4/6阻害薬に伴う消化器毒性のシグナル検出。

対象DB：FAERS

9. Immune-related adverse events in Hodgkin lymphoma treated with pembrolizumab or nivolumab: A disease-restricted US Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance analysis.

ホジキンリンパ腫におけるICI療法の免疫関連有害事象の調査。

対象DB：FAERS

10. The Real-World Safety Profile of Immune Checkpoint Inhibitors in Melanoma: FAERS Pharmacovigilance Analysis Complemented by Randomized Trial Evidence.

メラノーマ治療における免疫チェックポイント阻害薬の安全性解析。

対象DB：FAERS

11. Signal Detection and Pharmacovigilance Analysis of Tamoxifen, Clomiphene, and Letrozole in Polycystic Ovarian Syndrome: A FAERS Database Study.

PCOS排卵誘発薬3種における副作用シグナルと自発報告分析。

対象DB：FAERS

12. A post-marketing surveillance study of a human rabies vaccine in China (2020-2024).

中国におけるヒト狂犬病ワクチンの市販後安全性監視研究。

対象DB：FAERS,VAERS

13. Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Glucocorticoids: A Real-World Pharmacovigilance Analysis.

ICIとステロイドの併用における薬物相互作用と有害事象の解析。

対象DB：FAERS

14. Analysis of vaccine adverse events associated with rheumatoid arthritis: A pharmacovigilance study based on the VAERS database.

関節リウマチ患者における各種ワクチン接種後の有害事象解析。

対象DB：FAERS,VAERS

15. Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases.

アロマターゼ阻害薬とCDK4/6阻害薬併用時の有害事象評価。

対象DB：FAERS,JADER

16. Diclofenac-Associated Kounis Syndrome: A Systematic Review and Disproportionality Analysis of FAERS Database.

ジクロフェナク関連クーニス症候群のシグナル検出とレビュー。

対象DB：FAERS

17. Drug-specific differences in fatal adverse events among PARP inhibitors: a FAERS pharmacovigilance study.

FAERSを用いたPARP阻害薬間における致死性有害事象の比較。

対象DB：FAERS

18. Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study.

新規がん治療薬による薬剤性間質性肺疾患の不均衡分析調査。

対象DB：FAERS

19. Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison.

ミリキズマブの市販後安全性プロファイルに関する多国籍DB解析。

対象DB：FAERS,JADER,KAERS

20. Safety Profile Comparison of Androgen Receptor Pathway Inhibitors: A Pharmacovigilance Signal Detection Analysis Using Disproportionality Methods and Age-Stratified Comparison of 37,875 FAERS Reports.

アンドロゲン受容体阻害薬間の安全性プロファイル比較解析。

対象DB：FAERS

21. Pancreatitis Associated With Givosiran: A Real-World Pharmacovigilance Study Based on the FAERS and EudraVigilance Databases.

ギボシランに伴う急性膵炎のFAERSに基づく市販後安全性調査。

対象DB：EudraVigilance

22. Hepatic Safety Profile of Atomoxetine and Methylphenidate in Patients with ADHD: Disproportionality Analysis Using EudraVigilance Database Data.

ADHD治療薬アトモキセチン等の肝安全性に関する比較調査。

対象DB：EudraVigilance

23. Cardiac arrest associated with anaesthetic agents: a disproportionality analysis of the World Health Organization VigiBase Database.

麻酔薬使用に伴う心停止の不均衡分析による副作用シグナル検出。

対象DB：VigiBase

24. VigiBase suggests that the number of deaths by suicide in adolescents with schizophrenia as a result of not taking clozapine may be much higher than the number of deaths from agranulocytosis after taking clozapine.

VigiBaseに基づく統合失調症思春期患者の自殺リスク調査。

対象DB：VigiBase

25. Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments-A VigiBase Disproportionality Analysis Study.

妊娠期乳がんに対する全身療法に伴う母体および新生児の合併症。

対象DB：VigiBase

26. Age-stratified risk of major systemic complications following unicompartmental versus total knee arthroplasty: a nationwide cohort study.

単顆型対全人工膝関節置換術後の年齢層別全身合併症リスク比較。

対象DB：DPC

27. Advanced Thymoma and Advanced Thymic Carcinoma Treatment Practices in 2018-2022: A Nationwide Analysis in Japan.

日本における進行胸腺腫・胸腺癌の実態と治療パターンの解析。

対象DB：DPC

28. Left Ventricular Unloading With Impella Versus Intra-Aortic Balloon Pump in Cardiogenic Shock Requiring Venoarterial Extracorporeal Membrane Oxygenation.

心原性ショックでのImpella対IABPによる左室脱血効果比較。

対象DB：DPC

29. Real-world diagnostic pathways and treatment patterns for suspected lung cancer in Japan: a nationwide claims database analysis.

疑い例を含む肺がん患者の診断経路と治療パターンの実態調査。

対象DB：DPC

30. Safety of Early Rehabilitation Dose After Stroke on Composite Outcomes: Analysis of Nationwide Japanese Medical Claims Data.

脳卒中早期リハビリテーションの線量と複合転帰の安全性解析。

対象DB：DPC

31. Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.

日本におけるチルゼパチドの調剤パターンと用量構成推移の調査。

対象DB：NDB

32. Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan.

日本の乾癬患者における全身療法薬の処方パターン解析。

対象DB：MDV

33. Iron deficiency testing among people with incident heart failure in primary care.

英国の初発心不全患者における鉄欠乏検査の実施状況調査。

対象DB：CPRD

34. Incident Neutropenia in New Users of Different Non-opioid Analgesics: An Observational Propensity Score-Controlled Cohort Study.

非オピオイド鎮痛薬の新規使用者における好中球減少症リスク調査。

対象DB：CPRD

35. The SLICC/ACR damage index, assessed using a community-based electronic healthcare record, predicts mortality in SLE patients: results from the United Kingdom Clinical Practice Research Datalink.

地域電子カルテを用いたSLEダメージインデックスの自動算出検証。

対象DB：CPRD

36. Is potentially inappropriate prescribing in UK middle-aged adults associated with healthcare utilisation and mortality? A prospective cohort study of a 1.2 million patient cohort conducted in the clinical practice research datalink.

英国の中年成人における不適切処方の有病率と有害転帰との関連性。

対象DB：CPRD

37. Behcet's syndrome epidemiology in England: a real-world retrospective cohort analysis with a nested case-control study using linked UK primary and secondary care data.

英国におけるベーチェット病の発症率・有病率および臨床像の解析。

対象DB：CPRD